Aetion To Utilize the Foundation’s IBD Plexus® Data to Accelerate Real-World Data Studies for Biopharma Companies, Reducing the Time to Insight and Driving Medical Innovation for IBD
NEW YORK, NY, February 20, 2025 —Aetion, a global real-world evidence technology and analytics provider announced today that it has joined the Crohn's & Colitis Foundation's IBD Plexus® Research Program as a preferred analytics partner.
The Crohn’s & Colitis Foundation is the leading nonprofit organization dedicated to finding cures and improving the lives of people with inflammatory bowel disease (IBD), which impacts approximately 1 in 100 Americans. IBD Plexus, the Foundation’s research accelerator, houses the most comprehensive collection of IBD patient data and biosamples in the world. By connecting hundreds of researchers with the right data, expertise, and technology, IBD Plexus significantly accelerates innovation, reducing the time it takes to discover new treatments and advancing the journey toward IBD cures.
As a preferred partner, Aetion will utilize IBD Plexus data to accelerate real-world data (RWD) studies for biopharma companies, reducing the time to insight and driving medical innovation for IBD.
“This is the first time that Aetion has partnered with a patient organization as we are seeing disease-specific advocacy groups, which have amassed large amounts of data, increasingly interested in making that data available for the betterment of their patient populations,” said Wendy Turenne, chief data officer at Aetion. “Combining the Foundation’s diverse, rich data in IBD Plexus with our technology and expertise in real-world data allows us to quickly give our pharmaceutical and biotech customers the insights they need to accelerate IBD drug development. Speed is important as patients are waiting.”
IBD patients urgently need more effective and personalized treatments. Despite numerous biologic and small molecule therapies in advanced stages of development, significant unmet needs remain in managing these complex conditions. In this high-need IBD space, data customers are interested in more targeted approaches to therapy that connect clinical, patient-reported outcomes, and molecular data with linked biosamples. The partnership with IBD Plexus will streamline access to complex data, offering flexible analysis options through either self-service with Aetion® Substantiate or tech-enabled services. Key features include a measures library that defines IBD variables in collaboration with key opinion leaders, enhancing data analysis and standardization.
“Through our collaboration with the Foundation, we are leveraging the Aetion Evidence Platform® and our expertise in analyzing IBD Plexus complex data to enhance their offerings. This, in turn, will increase the return on investment for pharmaceutical companies utilizing IBD Plexus data," said Ashley Jaksa, commercial product lead for scientific services & HEOR markets at Aetion. “We believe this win-win approach is a model that could also benefit other patient organizations.”
IBD Plexus efficiently integrates diverse datasets from clinical settings, hospitals, laboratories, and patients' homes through longitudinal research and quality studies. This comprehensive approach creates valuable opportunities to connect research, care, and patient experiences. By linking decades of patient journey data with biosamples, IBD Plexus is transforming research into life-changing precision medicine strategies for inflammatory bowel disease.
“Our robust IBD data is enabling collaboration with outside partners to unlock the potential of emerging tech and fast-track scientific discoveries,” said Angela Dobes, senior vice president of IBD Plexus at the Foundation. “We are delighted to announce this strategic collaboration with Aetion, designed to enhance the value of IBD Plexus for the research community and ultimately improve patient outcomes.”
This partnership builds upon Aetion’s collaboration with the Foundation in 2022 to leverage RWD and real-world evidence to explore and understand the causes of IBD disease progression and assess the value of new IBD treatments.
For more information about Aetion’s offering, please contact us here. To learn more about Aetion, visit aetion.com and follow us on LinkedIn.